Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Selected reaction monitoring approach for validating peptide biomarkers.

Wang Q, Zhang M, Tomita T, Vogelstein JT, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13519-13524. doi: 10.1073/pnas.1712731114. Epub 2017 Dec 4.

2.

Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method.

Nie S, Yin H, Tan Z, Anderson MA, Ruffin MT, Simeone DM, Lubman DM.

J Proteome Res. 2014 Dec 5;13(12):6058-66. doi: 10.1021/pr500934u. Epub 2014 Nov 24.

3.

Multi-peptide nLC-PC-IDMS-SRM-based assay for the quantification of biomarkers in the chicken ovarian cancer model.

Andrews Kingon GL, Petitte JN, Muddiman DC, Hawkridge AM.

Methods. 2013 Jun 15;61(3):323-30. doi: 10.1016/j.ymeth.2013.04.004. Epub 2013 Apr 19.

4.

Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.

Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW.

J Proteomics. 2013 Aug 26;89:165-78. doi: 10.1016/j.jprot.2013.06.016. Epub 2013 Jun 21.

5.

MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma.

Lee JY, Kim JY, Cheon MH, Park GW, Ahn YH, Moon MH, Yoo JS.

J Proteomics. 2014 Feb 26;98:206-17. doi: 10.1016/j.jprot.2014.01.003. Epub 2014 Jan 14.

PMID:
24434586
6.

Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.

Hüttenhain R, Soste M, Selevsek N, Röst H, Sethi A, Carapito C, Farrah T, Deutsch EW, Kusebauch U, Moritz RL, Niméus-Malmström E, Rinner O, Aebersold R.

Sci Transl Med. 2012 Jul 11;4(142):142ra94. doi: 10.1126/scitranslmed.3003989.

7.

A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.

Tang HY, Beer LA, Chang-Wong T, Hammond R, Gimotty P, Coukos G, Speicher DW.

J Proteome Res. 2012 Feb 3;11(2):678-91. doi: 10.1021/pr200603h. Epub 2011 Nov 18.

8.

Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.

Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA.

J Proteome Res. 2011 May 6;10(5):2359-76. doi: 10.1021/pr101148r. Epub 2011 Mar 28.

9.
10.

Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.

Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, Milless BP, Goodlett DR, Rush J, Brentnall TA.

J Proteome Res. 2012 Mar 2;11(3):1937-48. doi: 10.1021/pr201117w. Epub 2012 Feb 8.

11.

Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach.

Xue H, Lü B, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J, Lai M.

J Proteome Res. 2010 Jan;9(1):545-55. doi: 10.1021/pr9008817.

PMID:
19924834
12.

Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study.

Bertuzzi M, Marelli C, Bagnati R, Colombi A, Fanelli R, Saieva C, Ceroti M, Bendinelli B, Caini S, Airoldi L, Palli D.

BMC Cancer. 2015 Feb 14;15:56. doi: 10.1186/s12885-015-1058-7.

13.

Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.

Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8. Epub 2003 Oct 1.

14.

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.

Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP.

BMC Cancer. 2013 Sep 3;13:404. doi: 10.1186/1471-2407-13-404.

15.

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.

Wang Q, Li D, Zhang W, Tang B, Li QQ, Li L.

Int J Biol Markers. 2011 Oct-Dec;26(4):262-73. doi: 10.5301/JBM.2011.8616.

PMID:
21928244
16.

Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.

Timms JF, Arslan-Low E, Kabir M, Worthington J, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Podust VN, Fourkala EO, Cubizolles M, Kronenberg F, Fung ET, Gentry-Maharaj A, Menon U, Jacobs I.

Proteomics Clin Appl. 2014 Dec;8(11-12):982-93. doi: 10.1002/prca.201400063. Epub 2014 Nov 10.

17.

Quantitative Proteomics Based on Optimized Data-Independent Acquisition in Plasma Analysis.

Nigjeh EN, Chen R, Brand RE, Petersen GM, Chari ST, von Haller PD, Eng JK, Feng Z, Yan Q, Brentnall TA, Pan S.

J Proteome Res. 2017 Feb 3;16(2):665-676. doi: 10.1021/acs.jproteome.6b00727. Epub 2017 Jan 3.

18.

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V.

Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.

19.

Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery.

Zhou C, Simpson KL, Lancashire LJ, Walker MJ, Dawson MJ, Unwin RD, Rembielak A, Price P, West C, Dive C, Whetton AD.

J Proteome Res. 2012 Apr 6;11(4):2103-13. doi: 10.1021/pr200636x. Epub 2012 Mar 12.

20.

Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.

Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M.

Clin Chem Lab Med. 2009;47(6):713-23. doi: 10.1515/CCLM.2009.158.

PMID:
19426140

Supplemental Content

Support Center